With this finding and the high potentiality of the benzimidazole nucleus toward cancer treatment-targeted NF-κB (Okolotowicz et al., 2010; Poltz and Naumann, 2012; Boggu et al., 2016; Jonak et al., 2016; Boggu et al., 2017; Dunphy et al., 2018; Błaszczak-Świątkiewicz, 2019), we were encouraged to increase the libraries of these analogs and assess them against different cancer cells. Here, NFKB1 is linked to cancer.